An Interview With Dagi Ben-Noon, CEO At Inspira Technologies

Listen to this article

Below is our recent interview with Dagi Ben-Noon, Co-Founder and CEO at Inspira Technologies (Nasdaq:IINN):

Q: Could you provide our readers with a brief introduction to your company?

A: Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. Inspira has a vision- Provide a new innovative way to treat respiratory failure. Every year approx. 20 million patients are admitted to ICUs due to respiratory failure, being intubated, placed in a medically induced coma, and undergo mechanical ventilation. Inspira’s ART system designed to prevent the need for mechanical ventilation (MV), whose disadvantages have become more apparent since the beginning of the COVID-19 pandemic. Inspira develops a cost-effective minimally invasive Extracorporeal Respiratory Support (ECRS) technology, which the company believes has the potential to utilize oxygen to rebalance patients’ saturation levels while they are awake.

Inspira’s ART system, which is based on ECRS technology, acts as external lungs, by withdrawing blood through a dual lumen cannula inserted into the jugular vein, enriching it with a high concentration of oxygen, removing CO2, and returning the enriched blood to rebalance patient’s saturation levels and take the load off the lungs. Inspira’s technology has the potential to prevent the need for mechanical ventilation.

Recommended: An Interview With Alex Cammarano, Director Of Operations At Eastra Health

Q: Any highlights on your recent announcement?

A: Inspira completed NASDAQ IPO last month, since than the company appointed a new medical board member to its advisory board, Dr. Dekel Stavi which considerable experience in Extracorporeal Life Support programs, and cardiology aspects of ICU’s patients, and we believe his experience will contribute Inspira in the next development stages. Inspira also announced the introduction of an innovative microbubble platform designed to extend the life of oxygenators products and potentially prevent blood clots when integrated into a treatment regimen.

Q: Can you give us more insights into your offering?

A: Inspira Technologies is now listed on the Nasdaq stock exchange under the ticker symbol “IINN”. The IPO was priced on July 13, 2021, with the official closing scheduled for Friday, July 16, 2021. The gross proceeds of the offering were approximately $16 million before deducting underwriting discounts, commissions, and offering expenses.

Q: What can we expect from your company in the next 6 months? What are your plans?

A: Inspira taking a multi-step approach to bring its ART system to the market. By the end of 2023, Inspira is planning on introduce the ART system to the market with the new intent of use. As we have two parallel paths that are linked, we will initially submit a 510k to one of our components at the end of 2022, and we plan to submit Inspira’s integrated system 510k at the end of that year. As part of Inspira’s strategy to reach this goal, and in parallel to pursuing regulatory approvals, Inspira is working on establish collaborations with strategic partners and globally ranked health centers, to provide endorsement and future clinical adoption of its ART system. In addition, Inspira explores collaborations with leading medical device companies, manufactures, and distributors. The development of a strategic team is key to enable Inspira to rapidly deploy the ART in the future.

Recommended: LocalFactor’s Mission Is To Help Brands Maximize, Scale And Create Value From Local Audiences

Q: What is the best thing about your company that people might not know about?

A: Passionate and professional team with an innovative vision and a track record of success in execution. A highly experienced management team with a proven track record of success. The chairman, Prof. Benad Goldwasser has 10 exits to his name, Dagi Ben-Noon, one of the Co-Founders, is a serial entrepreneur and was one of Nano Dimension (NNDM) Co-Founders. Joe Hayon, the second Co-Founders and the company’s CFO has extensive experience in executing M&As and strategic joint ventures, manufacturing, and operations to support high-growth delivery. The third Co-Founder is Dr. Udi Nussinovitch is the Chief Scientific Officer of the company. Udi is a board-certified Cardiologist, ICU Physician, and Cardiology Researcher, as well as an expert hyperbaric and diving physician.